Skip to main content

Table 1 (abstract P42). Dynamics of vitamin D levels in children with JIA after its 3-months supplementation М±m, ng/ml

From: Proceedings of the 27th European Paediatric Rheumatology Congress (PReS 2021)

Sings

vitamin D level

Significance of differences

before additional intake of vitamin D

after taking of vitamin D

general group

21,40±1,97

28,89±2,11

p<0,05

normal BMI

22,57±3,94

27,08±5,47

p<0,05

decreased BMI

17,69±3,15

30,01±6,26

p<0,05

increased BMI

25,02±5,73

25,72±4,74

p>0,05

oligoarthritis

24,69±1,89

31,42±2,30

Ñ€<0,05

polyarthritis

18,03±2,25

24,21±2,74

Ñ€>0,05

undifferentiated arthritis

22,24±2,46

25,32±3,01

Ñ€>0,05

inactive disease

22,56±4,95

24,57±5,87

p>0,05

moderate activity

25,38±3,78

25,56±3,79

p>0,05

average activity

25,45±3,89

30,35±4,78

p<0,05

high activity

22,49±3,45

27,61±4,12

p<0,05

MTX +

21,53±7,16

29,03±9,99

p<0,05

MTX -

22,67±2,86

23,03±3,42

p>0,05

Duration of MTX therapy:

 before 6 months

22,98±2,71

31,86±6,28

p<0,05

 7-12 months

21,27±3,24

28,82±8,34

p>0,05

 1-2 years

20,50±3,03

25,16±10,40

p>0,05

 3-5 years

20,87±2,71

21,53±3,74

p>0,05

Doses of MTX:

 less than 10 mg/m2

22,37±2,67

22,99±2,45

p>0,05

 10,1-12,4 mg/m2

21,09±2,78

32,22±3,74

p<0,05

 12,5-15 mg/m2

22,31±2,36

30,71±3,46

p<0,05